GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-09-01| Trials & Approvals

J&J’s HIV Vaccine Results Disappoint, Trial Halted But Search Continues

by Joy Lin
Share To

Johnson and Johnson has pulled the plug on its HIV vaccine trial after it was clear the shot did little to prevent HIV. The Phase 2 Imbokodo trial, which commenced in 2017, enrolled over 2,600 women in southern Africa who were at high risk of contracting HIV.

Besides J&J, the study had the backing of the National Institute of Allergy and Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation, and the HIV Vaccine Trials Network.

Over the course of a year, participants received four shots, two of J&J’s vaccine, and two boosters containing HIV protein formulations designed to trigger the immune response. The study results revealed the vaccine was only 25% effective — falling short of the goal of 50% efficacy set by the researchers.

The silver lining is that the vaccine was safe. No serious adverse events occurred during the trial, it was reported. 

Related Article: Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors

 

Blame the Virus, Not the Vaccine

 

J&J’s HIV vaccine technology uses the same adenovirus — a kind of common cold virus that’s been modified to not replicate in the body, as that found in their Ebola and COVID-19 vaccines.

Those vaccines were highly effective in preventing the respective diseases, so what went wrong in the case of HIV?

The fault lies not in the vaccine but in the elusiveness of the virus. HIV infects the immune cells of the body and uses many mechanisms to evade detection and destruction.

 

A Series of Unfortunate Setbacks 

 

Since HIV’s discovery in the 1980s, there has been a worldwide race to develop a vaccine that prevents viral infection. While effective treatments and preventative methods and medicine have been developed, a vaccine was still considered critical in winning the fight against HIV.

There had been many trials and just as many failures. Merck scrapped a Phase 2 clinical trial in 2007 after its STEP vaccine failed to prevent HIV infection. In 2009, the Thai military backed a study known as RV144 which investigated whether a combination of two vaccines ALVAC and AIDSVAX was effective in preventing HIV. Results reported an efficacy of 31%, which was deemed too low for the trial to continue.

 

Other Trials to Carry On 

 

Despite the latest setback, scientists remain hopeful.

“This is in no way the end of the search for an HIV vaccine,” said Mitchell Warren, executive director of HIV prevention advocacy organization AVAC. “We still hope for a positive outcome from the ongoing Mosaico and PrEPVacc studies.”

The Phase 3 Mosaico trial has been deemed different enough to be worth continuing. It is enrolling 3800 homosexual and transgender men across Europe and the Americas. The intervention includes 4 injections of the vaccine and 2 injections of the booster, which uses different protein formulations than that of the Imbokodo trial. 

The PrEPVacc study combines HIV vaccine candidates with PrEP (pre-exposure prophylaxis), an oral pill that has up to 99% efficacy in preventing HIV when taken daily. The African-led study is recruiting over 1600 participants that are at high risk of HIV infection.

In a separate development, Moderna will begin human trials of its HIV vaccine next month. The vaccine uses the same mRNA technology as its highly successful COVID-19 vaccine.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Scanning Some of 2024’s Biggest Medical Breakthroughs
2024-12-31
Antibody-Drug Conjugates: Connecting Drugs to Cancer Cells and Unlocking Billions in Market Opportunities
2024-11-06
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top